Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GDC-9545 versus physician's choice endocrine monotherapy in previously treated ER-positive, HER2-negative advanced breast cancer
MOH_2020-12-09_009345Phase 2Completed
- Sponsor
- Roche
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of giredestrant in breast cancer (2 arms), sponsored by Roche. Primary endpoint: Progression-free survival. Started Sep 2020; status: completed.
02
Drugs
giredestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on MOH_2020-12-09_009345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-12-09_009345.